Torus Biosystems is developing the next generation of POC molecular diagnostics for syndromic infectious diseases based on the novel integration of qPCR and microarray technologies that enable detection and quantification of DNA in under 30 minutes. The Synestia™ System employs the syndromic testing approach, which is faster and more accurate than conventional methods, and delivers rapid, comprehensive, sample-to-answer solutions at the patient point of care in a compact and portable system that supports decentralized healthcare settings. Torus Biosystems was spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University in 2020 to develop and commercialize the proprietary DNA/RNA detection technology developed by Wyss Core Faculty member, Peng Yin, PhD, Professor, Department of Systems Biology, Harvard Medical School, and Wyss Alumnus David Zhang, PhD, Associate Professor of Bioengineering, Rice University. Learn more about how Torus Bio can help improve patient outcomes, combat antibiotic resistance, and promote antimicrobial stewardship in a wide range of ambulatory settings including Hospital Outpatient and Emergency Departments and Long-Term Care facilities. Visit the website at www.torus.bio and connect with on social media @Twitter and @LinkedIn.